H & Y <3 UPDRS-III Bilateral STN + BMT: 32.7 BMT: 25.3
Bilateral STN + BMT: 7.2 BMT: 6.4
18
(i) UPDRS-III: 69% improvement in DBS versus worsening in BMT (). (ii) PDQ-39: 24% improvement in DBS versus 0% in BMT (). (iii) Levodopa dose: reduced by 57% in the DBS versus 12% in the BMT ().
H & Y Bilateral STN/GPi: 3.4, BMT: 3.3 UPDRS-III Bilateral STN/GPi: 43 BMT: 43.2
Bilateral STN/GPi: 10.8 BMT: 12.6
6
(i) UPDRS-III: 71% of DBS patients experienced clinically meaningful motor function versus 32% of BMT patients (). (ii) PDQ-39: DBS group had significant improvement ().
H & Y DBS: 3.1, BMT: 3.2 UPDRS-III DBS: 47.6, BMT: 48.6
DBS: 11.5 BMT: 11.2
12
(i) UPDRS-III: 36% improvement in the DBS group versus 2% in BMT (). (ii) PDQ-39: mean improvement compared with baseline was 5.0 for the DBS group versus 0.3 points in the BMT ().
(i) UPDRS-III: 56% improvement in the DBS group versus 4% in BMT (). (ii) PDQ-39: 26% improvement in the DBS group versus no improvement in the BMT group (). (iii) Levodopa induced motor complications: 61% improvement in the DBS group versus no improvement in the BMT group ().
H & Y STN + BMT: 2, BMT: 2 UPDRS-III STN + BMT: 25.3 BMT: 25.6
STN + BMT: 2.2 BMT: 2.1
24
(i) UPDRS-III: mean scores were not significantly different on or off therapy. (ii) Medication requirements in the DBS + BMT group were lower at all time points.
DBS: Deep Brain Stimulation; SNT: subthalamic nucleus; GPi: globus pallidus interna; BMT: best medical therapy.